Trial · NCT01674621
Results by group185
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 185
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months | Abaloparatide Transdermal (50 mcg) | -17.26 | Standard Deviation 22.86 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months | Abaloparatide Transdermal (100 mcg) | -8.42 | Standard Deviation 29.51 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months | Abaloparatide Transdermal (150 mcg) | -16.63 | Standard Deviation 25.11 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months | Abaloparatide Injection (80 mcg) | 10.28 | Standard Deviation 72.31 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | -6.76 | Standard Deviation 31.35 | Percent change | |
| Percent Change From Baseline in Serum Osteocalcin at 6 Months | Abaloparatide Transdermal (50 mcg) | -4.37 | Standard Deviation 19.36 | Percent change | |
| Percent Change From Baseline in Serum Osteocalcin at 6 Months | Abaloparatide Transdermal (100 mcg) | 6.67 | Standard Deviation 33.38 | Percent change | |
| Percent Change From Baseline in Serum Osteocalcin at 6 Months | Abaloparatide Transdermal (150 mcg) | -3.83 | Standard Deviation 22.01 | Percent change | |
| Percent Change From Baseline in Serum Osteocalcin at 6 Months | Abaloparatide Injection (80 mcg) | 69.54 | Standard Deviation 81.79 | Percent change | |
| Percent Change From Baseline in Serum Osteocalcin at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | -4.21 | Standard Deviation 27.55 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months | Abaloparatide Transdermal (50 mcg) | -12.76 | Standard Deviation 26.81 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months | Abaloparatide Transdermal (100 mcg) | 1.52 | Standard Deviation 57.29 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months | Abaloparatide Transdermal (150 mcg) | -6.78 | Standard Deviation 38.91 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months | Abaloparatide Injection (80 mcg) | 97.64 | Standard Deviation 172.52 | Percent change | |
| Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | -7.26 | Standard Deviation 35.49 | Percent change | |
| Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months | Abaloparatide Transdermal (50 mcg) | -2.61 | Standard Deviation 28.77 | Percent change | |
| Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months | Abaloparatide Transdermal (100 mcg) | 1.65 | Standard Deviation 48.66 | Percent change | |
| Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months | Abaloparatide Transdermal (150 mcg) | -8.22 | Standard Deviation 54.84 | Percent change | |
| Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months | Abaloparatide Injection (80 mcg) | 41.11 | Standard Deviation 104.12 | Percent change | |
| Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months | Abaloparatide Transdermal Placebo (0 mcg) | 9.42 | Standard Deviation 22.57 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01674621/results?page=2